drugset / Trial / NCT02923154

Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)

NCT02923154 ↗

Phase 2 Completed 48 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the efficacy, safety, tolerability and pharmacokinetics of multiple oral administration of MT-3995 in patients with NASH.

Timeline

Start
2016-09
Primary completion
2018-03
Completion
2019-04

Drugs

EvaluationDrugModalityDoseRoute
Subject MT-3995 Small molecule — Oral